Find, compare & contact
Rizatriptan API Manufacturers & Suppliers

Looking for Rizatriptan API 144034-80-0?

Description:

Here you will find a list of producers, manufacturers and distributors of Rizatriptan. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Rizatriptan 

Synonyms:

Risatriptan , Rizatriptan , Rizatriptanum , Rizatriptan benzoate  

Cas Number:

144034-80-0 

DrugBank number:

DB00953 

Unique Ingredient Identifier:

51086HBW8G

Rizatriptan is a type of Serotonin receptor agonists

Serotonin receptor agonists are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that have shown potential in the treatment of various medical conditions. These compounds work by binding to and activating serotonin receptors in the body, which play a crucial role in regulating mood, appetite, sleep, and other physiological functions. By stimulating these receptors, serotonin receptor agonists can modulate serotonin signaling and produce therapeutic effects.

One prominent application of serotonin receptor agonists is in the treatment of migraines. Migraine headaches are often associated with abnormal serotonin levels and receptor activity. Serotonin receptor agonists, such as triptans, bind to specific serotonin receptor subtypes (e.g., 5-HT1B and 5-HT1D) in the brain's blood vessels, causing vasoconstriction and reducing inflammation. This action helps alleviate the severe pain and other symptoms associated with migraines.

Additionally, serotonin receptor agonists are being investigated for their potential in the management of psychiatric disorders, such as depression and anxiety. These compounds can modulate serotonin transmission, leading to improved mood and reduced anxiety levels. Research is also exploring their role in treating other conditions like irritable bowel syndrome (IBS), fibromyalgia, and cluster headaches.

As the development of serotonin receptor agonists progresses, scientists are focusing on optimizing their selectivity and potency while minimizing potential side effects. Pharmaceutical companies are actively engaged in synthesizing novel compounds and conducting clinical trials to assess their efficacy and safety profiles. The ongoing research and development in this subcategory hold promise for improved treatment options and enhanced patient outcomes in various serotonin-related disorders.

Rizatriptan (Serotonin receptor agonists), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• LGM Pharma from United States, product country of origin World
• SETV Global from India, product country of origin India
• TIEFENBACHER API + Ingredients from Germany, product country of origin Unknown
• Alkem Labs. from India, product country of origin India
• Unimark Remedies from India, product country of origin India
• Apotex Pharmachem from India, product country of origin India
• Unichem Labs. from India, product country of origin Unknown
• Natco Pharma from India, product country of origin India
• Syn-tech Chem from Taiwan, product country of origin Taiwan
• Zhejiang Supor from China, product country of origin China
• Cipla from India, product country of origin Unknown
• Emcure Pharma from India, product country of origin India
• Sun Pharma from India, product country of origin India
• Mylan from India, product country of origin India
• Hetero Drugs from India, product country of origin Unknown

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.